707 (3SBio)

N/A

Report date: 2026/05/23 20:00:57

Base Information

Drug Name707 (3SBio)
Drug Alias NameSSGJ-707SSGJ707707PF-08634404
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionVascular endothelial growth factor inhibitorsProgrammed cell death protein 1 inhibitors
TargetsProgrammed cell death protein 1Vascular endothelial growth factor
Therapy Area/IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[20] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[27] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator Companies3sbio Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesPfizer (Beijing) Research and Development Co LtdPfizer IncDansheng Pharmaceutical Technology (Shanghai) Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[19] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A